Fortschr Neurol Psychiatr 2017; 85(08): 450-462
DOI: 10.1055/s-0043-115644
Skripte der Botulinumtoxin-Akademie
Georg Thieme Verlag KG Stuttgart · New York

Die Behandlung der laryngealen Dystonie mit Botulinumtoxin

Treatment of laryngeal dystonia with botulinum toxin
Arno Olthoff
1   Phoniatrie und Pädaudiologie, Klinik für Hals-, Nasen- und Ohrenheilkunde, Universitätsmedizin Göttingen
,
Maria Grosheva
2   Klinik für Hals-, Nasen- und Ohrenheilkunde, Universitätsklinik Köln
,
Gerhard Reichel
3   Kompetenzzentrum für Bewegungsstörungen an der Paracelsusklinik Zwickau
,
Gerd Fabian Volk
4   Klinik für Hals-, Nasen- und Ohrenheilkunde, Fazialis-Nerv-Zentrum Jena, Universitätsklinikum Jena
,
Rainer Laskawi
5   Klinik für Hals-, Nasen- und Ohrenheilkunde, Universitätsmedizin Göttingen
› Institutsangaben
Weitere Informationen

Publikationsverlauf

12/21/2016

06/29/2017

Publikationsdatum:
25. August 2017 (online)

Zusammenfassung

Die Behandlung der laryngealen Dystonie mit Botulinumtoxin ist erfolgreich und wird von den Kostenträgern übernommen. Eine qualitativ gute Behandlung sollte jedem Patienten garantiert werden und deshalb ist es wichtig, generelle Standards im Expertenkreis zu erstellen. In dem hier vorliegenden Artikel werden verschiedene Aspekte des Krankheitsbildes „Spasmodische Dysphonie“ bzw. „Laryngeale Dystonie“ von Experten beleuchtet und diskutiert. Hierzu zählen neuere Erkenntnisse über die Ätiologie, anatomische Besonderheiten, Standards in der Diagnostik und der Therapie sowie auch Punkte, die noch in der Diskussion sind.

Abstract

The treatment of laryngeal dystonias with botulinum toxin is successful. Every patient suffering from a laryngeal dystonia should be assured of high quality therapeutic intervention. Therefore it is important to establish general standards by experts in this field. In this connection, we want to focus here on different relevant aspects of laryngeal dystonias. This includes new aspects in etiology, anatomical landmarks for the injection, standards in diagnostics and therapy and finally open issues needing discussion.

 
  • Literatur

  • 1 Mittermaier R. [Psychogenic dysphonia in adolescents]. Z Laryngol Rhinol Otol 1957; 36: 60-63
  • 2 Aronson AE, Brown JR, Litin EM. et al. Spastic dysphonia. II. Comparison with essential (voice) tremor and other neurologic and psychogenic dysphonias. J Speech Hear Disord 1968; 33: 219-231
  • 3 Brodnitz FS. Spastic dysphonia. Ann Otol Rhinol Laryngol 1976; 85: 210-214
  • 4 Ludlow CL, Adler CH, Berke GS. et al. Research priorities in spasmodic dysphonia. Otolaryngol Head Neck Surg 2008; 139: 495-505
  • 5 Baylor CR, Yorkston KM, Eadie TL. et al. The psychosocial consequences of BOTOX injections for spasmodic dysphonia: a qualitative study of patients’ experiences. J Voice 2007; 21: 231-247
  • 6 Hu A, Isetti D, Hillel AD. et al. Disease-specific self-efficacy in spasmodic dysphonia patients. Otolaryngol Head Neck Surg 2013; 148 (03) 450-5
  • 7 Feldmann H. Das Gutachten des Hals-Nasen-Ohren-Arztes. 3. Auflage. Georg Thieme Verlag; Stuttgart New York: 1994: 113
  • 8 Warner TT. The Epidemiological Study of Dystonia in Europe (ESDE) Collaborative Group. A prevalence study of primary dystonia in eight European countries. J Neurol 2000; 247 (10) 787-792
  • 9 Konkiewitz C. Epidemiologie der Dystonie in München. Dissertation an der TU München 2001: 1-51
  • 10 Castelon Konkiewitz E, Trender-Gerhard I, Kamm C. et al. Service-based survey of dystonia in munich. Neuroepidemiology 2002; 21: 202-206
  • 11 Asgeirsson H, Jakobsson F, Hjaltason H. et al. Prevalence study of primary dystonia in Iceland. Mov Disord 2006; 21: 293-298
  • 12 Roy N, Gouse M, Mauszycki SC. et al. Task specificity in adductor spasmodic dysphonia versus muscle tension dysphonia. Laryngoscope 2005; 115 (02) 311-316
  • 13 Grillone GA, Chan T. Laryngeal dystonia. Otolaryngol Clin North Am 2006; 39: 87-100
  • 14 Weiss EM, Hershey T, Karimi M. et al. Relative risk of spread of symptoms among the focal onset primary dystonias. Mov Disord 2006; 21: 1175-1181
  • 15 Defazio G, Berardelli A, Hallett M. Do primary adult-onset focal dystonias share aetiological factors?. Brain 2007; 130 (Pt 5) 1183-1193
  • 16 Rosenkranz K, Williamon A, Butler K. et al. Pathophysiological differences between musician’s dystonia and writer’s cramp. Brain 2005; 128 (Pt 4) 918-931
  • 17 Berardelli A. New advances in the pathophysiology of focal dystonias. Brain 2006; 129 (Pt 1) 6-7
  • 18 Torres-Russotto D, Perlmutter JS. Task-specific Dystonias. Ann N Y Acad Sci 2008; 1142: 179-199
  • 19 Simonyan K, Ludlow CL. Abnormal activation of the primary somatosensory cortex in spasmodic dysphonia: An fMRI Study. Cereb Cortex 2010; 20 (11) 2749-2759
  • 20 Simonyan K, Tovar-Moll F, Ostuni J. et al. Focal white matter changes in spasmodic dysphonia: A combined DTI and neuropathological study. Brain 2008; 131: 447-459
  • 21 Dedo HH, Townsend JJ, Izdebski K. Current evidence for the organic etiology of spastic dysphonia. Otolaryngology 1978; 86 ORL-875–880
  • 22 Hallett M. Physiology of basal ganglia disorders: an overview. Can J Neurol Sci 1993; 20: 177-183
  • 23 Hallett M. Is dystonia a sensory disorder?. Ann Neurol 1995; 38: 139-140
  • 24 Hallett M. How does botulinum toxin work?. Ann Neurol 2000; 48: 7-8
  • 25 Schaefer S, Freeman F, Finitzo T. et al. Magnetic resonance imaging findings and correlations in spasmodic dysphonia patients. Ann Otol Rhinol Laryngol 1985; 94: 595-601
  • 26 Kaji R, Rothwell JC, Katayama M. et al. Tonic vibration reflex and muscle afferent block in writer’s cramp. Ann Neurol 1995; 38: 155-162
  • 27 Simonyan K, Ludlow CL. Abnormal structure–function relationship in spasmodic dysphonia. Cereb Cortex 2012; 22: 417-425
  • 28 Ali SO, Thomassen M, Schulz GM. et al. Alterations in CNS activity induced by botulinum toxin treatment in spasmodic dysphonia: an H215O PET study. J Speech Lang Hear Res 2006; 49: 1127-1146
  • 29 Rosales RL, Dressler D. On muscle spindles, dystonia and botulinum toxin. Eur J Neurol 2010; 17: 71-80
  • 30 Aniss AM, Diener HC, Hore J. et al. Behavior of human muscle receptors when reliant on proprioceptive feedback during standing. J Neurophysiol 1990; 64: 661-670
  • 31 Bielamowicz S, Ludlow CL. Effects of botulinum toxin on pathophysiology in spasmodic dysphonia. Ann Otol Rhinol Laryngol 2000; 109: 194-203
  • 32 Aniss AM, Diener HC, Hore J. et al. Reflex activation of muscle spindles in human pretibial muscles during standing. J Neurophysiol 1990; 64 (02) 671-679
  • 33 Trompetto C, Curra A, Buccolieri A. et al. Botulinum toxin changes intrafusal feedback in dystonia: a study with the tonic vibration reflex. Mov Disord 2006; 21: 777-782
  • 34 Rosales RL, Arimura K, Takenaga S. et al. Extrafusal and intrafusal muscle effects in experimental botulinum toxin-A injection. Muscle Nerve 1996; 19: 488-496
  • 35 Pitman MJ. Treatment of Spasmodic Dysphonia With a Neuromodulating Electrical Implant. Laryngoscope 2014; 124: 2537-2543
  • 36 Blitzer A, Brin M, Stewart C. Botulinum Toxin Management of Spasmodic Dysphonia (Laryngeal Dystonia): A 12-Year Experience in More Than 9000 Patients. Laryngoscope 1998; 108: 1435-1441
  • 37 Mor N, Blitzer A. Diagnosis and treatment of laryngeal dystonia: past, present and future directions. Tremor Other Hyperkinet Mov 2016; 6 doi: 10.7916/D8G160J5
  • 38 Bressman SB, De Leon D, Raymond D. et al. Secondary dystonia and the DYTi gene. Neurology 1997; 48: 1572-1577
  • 39 Ozelius LJ, Hewett JW, Page CE. et al. The gene (DYT 1) for early-onset torsion dystonia encodes a novel protein related to the Clp protease/heat shock family. Adv Neurol 1998; 78: 93-105
  • 40 Kramer PL, de Leon D, Ozelius L. et al. Dystonia gene in Ashkenazi Jewish population is located on chromosome 9q32–34. Ann Neurol 1990; 27: 114-120
  • 41 Ozelius LJ, Kramer PL, de Leon D. et al. Strong allelic association between the torsion dystonia gene (DYT 1) and loci on chromosome 9q34 in Ashkenazi Jews. Am J Hum Genet 1992; 50: 619-628
  • 42 Rostasy K, Augood SJ, Hewett JW. TorsinA protein and neuropathology in early onset generalized dystonia with GAG deletion. Neurobiol Dis 2003; 12: 11-24
  • 43 Ozelius LJ, Hewett JW, Page CE. et al. The early-onset torsion dystonia gene (DYT 1) encodes an ATP-binding protein. Nat Genet 1997; 17: 40-48
  • 44 Ozelius L, Kramer PL, Moskowitz CB. et al. Human gene for torsion dystonia located on chromosome 9q32–q34. Neuron 1989; 2: 1427-1434
  • 45 Gasser T, Bove CM, Ozelius LJ. et al. Haplotype analysis at the DYT 1 locus in Ashkenazi Jewish patients with occupational hand dystonia. Mov Disord 1996; 11: 163-166
  • 46 Risch NJ, Bressman SB, de Leon D. et al. Segregation analysis of idiopathic torsion dystonia in Ashkenazi Jews suggests autosomal dominant inheritance. Am J Hum Genet 1990; 46: 533-538
  • 47 Klein C, Brin MF, de Leon D. et al. De novo mutations (GAG deletion) in the DYT 1 gene in two non-Jewish patients with early-onset dystonia. Hum Mol Genet 1998; 7: 1133-1136
  • 48 Lee WW, Ahn TB, Chung SJ. et al. Phenotypic differences in Dyt1 between ethnic groups. Curr Neurol Neurosci Rep 2012; 12: 341-347
  • 49 Cooper MH. Anatomy of the Larynx. In: Blitzer A, Brin MF, Ramig LO. ed. Neurological Disorders of the Larynx. 2nd Edition. New York: Thieme Medical Publishers, Inc; 2009: 3-9
  • 50 Sañudo JR, Maranillo E, León X. et al. An anatomical study of anastomoses between the laryngeal nerves. Laryngoscope 1999; 109 (06) 983-987
  • 51 Olthoff A, Schiel R, Kruse E. The supraglottic nerve supply: an anatomic study with clinical implications. Laryngoscope 2007; 117 (11) 1930-1933
  • 52 Volk GF, Hagen R, Pototschnig C. et al. Laryngeal electromyography: a proposal for guidelines of the European Laryngological Society. Eur Arch Otorhinolaryngol 2012; 269 (10) 2227-2245
  • 53 Blitzer A, Crumley RL, Dailey S. et al. Recommendation of the Neurolaryngology Study Group on Laryngeal Electromyography. Otolaryngol – Head Neck Surg 2009; 140 (06) 782-793
  • 54 Schlotthauer G, Torres ME, Jackson-Menaldi MC. A pattern recognition approach to spasmodic dysphonia and muscle tension dysphonia automatic classification. J Voice 2010; 24: 346-353
  • 55 Blitzer A, Brin MF. Laryngeal dystonia: A series with Botulinum toxin therapy. Ann Otol Rhinol Laryngol 1991; 100: 85-89
  • 56 Zwirner P, Dressler D, Kruse E. Spasmodic laryngeal dyspnea: a rare manifestation of laryngeal dystonia. Eur Arch Otorhinolaryngol 1997; 254: 242-245
  • 57 Marion MH, Klap P, Cohen M. et al. Stridor and focal laryngeal dystonia. The Lancet 1992; 339: 457-458
  • 58 Braun N, Abd A, Baer J. et al. Dyspnea in dystonia. Chest 1995; 107: 1309
  • 59 Klotz DA, Maronian NC, Waugh PF. et al. Findings of multiple muscle involvement in a study of 214 patients with laryngeal dystonia using fine-wire electromyography. Ann Otol Rhinol Laryngol 2004; 113 (08) 602-612
  • 60 Hillel AD, Maronian NC, Waugh PF. et al. Treatment of the interarytenoid muscle with botulinum toxin for laryngeal dystonia. Ann Otol Rhinol Laryngol 2004; 113 (05) 341-348
  • 61 Persaud R, Garas G, Silva S. et al. An evidence-based review of botulinum toxin (Botox) applications in non-cosmetic head and neck conditions. JRSM Short Rep 2013; 4 (02) 10
  • 62 Thenganatt MA, Fahn S. Botulinum toxin for the treatment of movement disorders. Curr Neurol Neurosci Rep 2012; 12 (04) 399-409
  • 63 Christensen PM, Heimdal JH, Christopher KL. et al. ERS/ELS/ACCP Task Force on Inducible Laryngeal Obstructions. ERS/ELS/ACCP 2013 international consensus conference nomenclature on inducible laryngeal obstructions. Eur Respir Rev 2015; 24 (137) 445-450
  • 64 Mehta RP, Goldman SN, Orloff LA. Long-term therapy for spasmodic dysphonia: acoustic and aerodynamic outcomes. Arch Otolaryngol Head Neck Surg 2001; 127 (04) 393-399
  • 65 Truong DD, Rontal M, Rolnick M. et al. Double-blind controlled study of botulinum toxin in adductor spasmodic dysphonia. Laryngoscope 1991; 101: 630-634
  • 66 Zwirner P, Murry T, Swenson M. et al. Acoustic changes in spasmodic dysphonia after botulinum toxin injection. J Voice 1991; 5: 78-84
  • 67 Edgar JD, Sapienza CM, Bidus K. et al. Acoustic measures of symptoms in abductor spasmodic dysphonia. J Voice 2001; 15: 362-372
  • 68 Rosow DE, Parikh P, Vivero RJ. et al. Considerations for Initial Dosing of Botulinum Toxin in Treatment of Adductor Spasmodic Dysphonia. Otolaryngol Head Neck Surg 2013; 148 (06) 1003-1006
  • 69 Novakovic D, Waters HH, D’Elia JB. et al. Botulinum toxin treatment of adductor spasmodic dysphonia: longitudinal functional outcomes. Laryngoscope 2011; 121: 606-612
  • 70 Paniello RC, Edgar JD, Perlmutter JS. Vocal exercise versus voice rest following botulinum toxin injections: a randomized crossover trial. Ann Otol Rhinol Laryngol 2009; 118: 759-763
  • 71 Silverman EP, Garvan C, Shrivastav R. et al. Combined Modality Treatment of Adductor Spasmodic Dysphonia. J Voice 2012; 26 (01) 77-86
  • 72 Tanner K, Roy N, Merrill RM. et al. Spasmodic dysphonia: onset, course, socioemotional effects, and treatment response. Ann Otol Rhinol Laryngol 2011; 120 (07) 465-473
  • 73 Braden MN, Johns MM, Klein AM. et al. Assessing the effectiveness of botulinum toxin injections for adductor spasmodic dysphonia: clinician and patient perception. J Voice 2010; 24: 242-249
  • 74 Gama AC, Menezes LN, Maia AA. et al. Voice related quality of life after botulinum toxin injection for spasmodic dysphonia. Rev Laryngol Otol Rhinol (Bord) 2010; 131: 39-44
  • 75 Siemons-Lühring DI, Moerman M, Martens JP. et al. Spasmodic dysphonia, perceptual and acoustic analysis: presenting new diagnostic tools. Eur Arch Otorhinolaryngol 2009; 266: 1915-1922
  • 76 Wingate JM, Ruddy BH, Lundy DS. et al. Voice handicap index results for older patients with adductor spasmodic dysphonia. J Voice 2005; 19: 124-131
  • 77 Cannito MP, Woodson GE, Murry T. et al. Perceptual analyses of spasmodic dysphonia before and after treatment. Arch Otolaryngol Head Neck Surg 2004; 130: 1393-1399
  • 78 Rubin AD, Wodchis WP, Spak C. et al. Longitudinal effects of Botox injections on voice-related quality of life (V-RQOL) for patients with adductory spasmodic dysphonia: part II. Arch Otolaryngol Head Neck Surg 2004; 130: 415-420
  • 79 Benninger MS, Gardner G, Grywalski C. Outcomes of botulinum toxin treatment for patients with spasmodic dysphonia. Arch Otolaryngol Head Neck Surg 2001; 127 (09) 1083-1085
  • 80 Bhattacharyya N, Tarsy D. Impact on quality of life of botulinum toxin treatments for spasmodic dysphonia and oromandibular dystonia. Arch Otolaryngol Head Neck Surg 2001; 127: 389-392
  • 81 Hogikyan ND, Wodchis WP, Spak C. et al. Longitudinal effects of botulinum toxin injections on voice-related quality of life (V-RQOL) for patients with adductory spasmodic dysphonia. J Voice 2001; 15: 576-586
  • 82 Whurr R, Lorch M, Fontana H. et al. The use of botulinum toxin in the treatment of adductor spasmodic dysphonia. J Neurol Neurosurg Psychiatry 1993; 56: 526-530
  • 83 Zwirner P, Murry T, Woodson GE. Perceptual-acoustic relationships in spasmodic dysphonia. J Voice 1993; 7: 165-171
  • 84 Morzaria S, Damrose EJ. A Comparison of the VHI, VHI-10, and V-RQOL for Measuring the Effect of Botox Therapy in Adductor Spasmodic Dysphonia. J Voice 2012; 26 (03) 378-380
  • 85 Dejonckere PH, Neumann KJ, Moerman MB. et al. Tridimensional assessment of adductor spasmodic dysphonia pre- and post-treatment with Botulinum toxin. Eur Arch Otorhinolaryngol 2012; 269 (04) 1195-1203
  • 86 Cannito MP, Doiuchi M, Murry T. et al. Perceptual structure of adductor spasmodic dysphonia and its acoustic correlates. J Voice. 2012 26. (6): 818.e5–13
  • 87 Watts C, Whurr R, Nye C. Botulinum toxin injections for the treatment of spasmodic dysphonia (Review). The Cochrane Library 2010; 1-25
  • 88 Watts CR, Truong DD, Nye C. Evidence for the effectiveness of botulinum toxin for spasmodic dysphonia from high-quality research designs. J Neural Transm 2008; 115: 625-630
  • 89 Dedo HH, Izdebski K. Intermediate results of 306 recurrent laryngeal nerve sections for spastic dysphonia. Laryngoscope 1983; 93: 9-16
  • 90 Dedo HH, Izdebski K. Problems with surgical (RLN section) treatment of spastic dysphonia. Laryngoscope 1983; 93: 268-271
  • 91 Chan SW, Baxter M, Oates J. et al. Long-term results of type II thyroplasty for adductor spasmodic dysphonia. Laryngoscope 2004; 114: 1604-1608
  • 92 Sanuki T, Isshiki N. Outcomes of type II thyroplasty for adductor spasmodic dysphonia: analysis of revision and unsatisfactory cases. Acta Otolaryngol 2009; 129: 1287-1293
  • 93 Mendelsohn AH, Berke GS. Surgery or botulinum toxin for adductor spasmodic dysphonia: a comparative study. Ann Otol Rhinol Laryngol 2012; 121 (04) 231-238
  • 94 DeConde AS, Long JL, Armin BB. et al. Functional reinnervation of vocal folds after selective laryngeal adductor denervation-reinnervation surgery for spasmodic dysphonia. J Voice 2012; 26 (05) 602-603
  • 95 Chhetri DK, Mendelsohn AH, Blumin JH. et al. Long-term follow-up results of selective laryngeal adductor denervation-reinnervation surgery for adductor spasmodic dysphonia. Laryngoscope 2006; 116: 635-642
  • 96 Hussain A, Shakeel M. Selective lateral laser thyroarytenoid myotomy for adductor spasmodic dysphonia. J Laryngol Otol 2010; 124: 886-891
  • 97 Su CY, Lai CC, Wu PY. et al. Transoral laser ventricular fold resection and thyroarytenoid myoneurectomy for adductor spasmodic dysphonia: long-term outcome. Laryngoscope 2010; 120: 313-318
  • 98 Tsuji DH, Takahashi MT, Imamura R. et al. Endoscopic laser thyroarytenoid myoneurectomy in patients with adductor spasmodic dysphonia: a pilot study on long-term outcome on voice quality. J Voice. 2012 26. (5): 666.e7–12
  • 99 Smith ME, Roy N, Wilson C. Lidocaine block of the recurrent laryngeal nerve in adductor spasmodic dysphonia: a multidimensional assessment. Laryngoscope 2006; 116: 591-595
  • 100 Lyons MK, Boucher OK, Evidente VGH. Spasmodic Dysphonia and Thalamic Deep Brain Stimulation: Long-term Observations, Possible Neurophysiologic Mechanism and Comparison of Unilateral Versus Bilateral Stimulation. J Neurol Neurophysiol 2010; 1: 106 doi:10.4172/2155-9562.1000106
  • 101 Aydin S, Abuzayed B, Varlibas F. et al. Treatment of homocystinuria-related dystonia with deep brain stimulation: a case report. Stereotact Funct Neurosurg 2011; 89 (04) 210-213
  • 102 Batla A, Stamelou M, Bhatia KP. Treatment of focal dystonia. Curr Treat Options Neurol 2012; 14 (03) 213-329
  • 103 Barkmeier-Kraemer J, Lato A, Wiley K. Development of a speech treatment program for a client with essential vocal tremor. Semin Speech Lang 2011; 32: 43-57
  • 104 Deepak R, Mathew H, Koshy M. Effectiveness of acupuncture in cervical dystonia. Acupunct Med 2010; 28: 94-96
  • 105 Mathieson L. The evidence for laryngeal manual therapies in the treatment of muscle tension dysphonia. Curr Opin Otolaryngol Head Neck Surg 2011; 19 (03) 171-176
  • 106 Jankovic J. Treatment of dystonia. Lancet Neurol 2006; 5: 864-872
  • 107 Nemeth AH. Dystonia Overview. In: University of Washington; Seattle: Pagon RA, Bird TD, Dolan CR: 2006
  • 108 Matthes P, Kruegel J, Karapantzou C. et al. Verwendung von Botulinumtoxin an HNO-Kliniken in Deutschland. HNO 2010; 58 (05) 452-458
  • 109 Beschluss des Gemeinsamen Bundesausschusses über eine Änderung der Arzneimittel-Richtlinie (AM-RL). Anlage VI – Off-Label-Use Clostridium botulinum Toxin Typ A (OnabotulinumtoxinA, AbobotulinumtoxinA) bei Spasmodischer Dysphonie (Laryngealer Dystonie) vom 21. März 2013. BAnz AT 11.06.2013 B1. https://www.g-ba.de/downloads/39-261-1678/2013-03-21_AM-RL-VI_Botox-Dysphonie_BAnz.pdf
  • 110 Dressler D. Botulinum toxin for treatment of dystonia. Eur J Neurol 2010; 17 (Suppl. 01) 88-96
  • 111 Eskander A, Fung K, McBride S. et al. Current practices in the management of adductor spasmodic dysphonia. J Otolaryngol Head Neck Surg 2010; 39: 622-630
  • 112 de Paiva A, Meunier FA, Molgó J. et al. Functional repair of motor endplates after botulinum neurotoxin type A poisoning: biphasic switch of synaptic activity between nerve sprouts and their parent terminals. Proc Natl Acad Sci USA 1999; 96: 3200-3205
  • 113 Ford CN, Bless DM, Lowery JD. Indirect laryngoscopic approach for injection of botulinum toxin in spasmodic dysphonia. Otolaryngol Head Neck Surg 1990; 103: 752-758
  • 114 Hussain A, Thiel G, Shakeel M. Trans-nasal injection of botulinum toxin. J Laryngol Otol 2009; 123: 783-785
  • 115 Rhew K, Fiedler DA, Ludlow CL. Technique for injection of botulinum toxin through the flexible nasolaryngoscope. Otolaryngol Head Neck Surg 1994; 111: 787-794
  • 116 Casserly P, Timon C. Botulinum toxin A injection under electromyographic guidance for treatment of spasmodic dysphonia. J Laryngol Otol 2008; 122: 52-56
  • 117 Jeffcoat BT, Schweinfurth JM. Efficacy of a portable, audible-only electromyography device in the treatment of spasmodic dysphonia. Laryngoscope 2008; 118: 942-943
  • 118 García Ruiz PJ, Cenjor Español C, Sanchez Bernardos V. et al. Botulinum toxin treatment for spasmodic dysphonia: percutaneous versus transoral approach. Clin Neuropharmacol 1998; 21: 196-198
  • 119 García Ruiz PJ, Cenjor Español C, Sánchez Pernaute R. et al. [Laryngeal dystonia. Comparison of transcutaneous and transoral injection of botulinum toxin]. Neurologia 1996; 11: 216-219
  • 120 Adams SG, Hunt EJ, Irish JC. et al. Comparison of botulinum toxin injection procedures in adductor spasmodic dysphonia. J Otolaryngol 1995; 24: 345-351
  • 121 Green DC, Berke GS, Ward PH. et al. Point-touch technique of botulinum toxin injection for the treatment of spasmodic dysphonia. Ann Otol Rhinol Laryngol 1992; 101 (11) 883-887
  • 122 Morzaria S, Damrose EJ. The point-touch technique for botulinum toxin injection in adductor spasmodic dysphonia: quality of life assessment. J Laryngol Otol 2011; 125 (07) 714-718
  • 123 Fulmer SL, Merati AL, Blumin JH. Efficacy of laryngeal botulinum toxin injection: comparison of two techniques. Laryngoscope 2011; 121 (09) 1924-1928
  • 124 Boutsen F, Cannito MP, Taylor M. et al. Botox treatment in adductor spasmodic dysphonia: a meta-analysis. J Speech Lang Hear Res 2002; 45: 469-481
  • 125 Kendall KA, Leonard RJ. Interarytenoid muscle botox injection for treatment of adductor spasmodic dysphonia with vocal tremor. J Voice 2011; 25: 114-119
  • 126 Rosen CA, Murry T. Botox for hyperadduction of the false vocal folds: a case report. J Voice 1999; 13: 234-239
  • 127 Schönweiler R, Wohlfarth K, Dengler R. et al. Supraglottal injection of botulinum toxin type A in adductor type spasmodic dysphonia with both intrinsic and extrinsic hyperfunction. Laryngoscope 1998; 108: 55-63
  • 128 Kendall KA, Leonard RJ. Treatment of ventricular dysphonia with botulinum toxin. Laryngoscope 1997; 107: 948-953
  • 129 Elmiyeh B, Prasad VM, Upile T. et al. A single-centre retrospective review of unilateral and bilateral Dysport injections in adductor spasmodic dysphonia. Logoped Phoniatr Vocol 2010; 35: 39-44
  • 130 Upile T, Elmiyeh B, Jerjes W. et al. Unilateral versus bilateral thyroarytenoid Botulinum toxin injections in adductor spasmodic dysphonia: a prospective study. Head Face Med 2009; 5: 20
  • 131 Stong BC, DelGaudio JM, Hapner ER. et al. Safety of simultaneous bilateral botulinum toxin injections for abductor spasmodic dysphonia. Arch Otolaryngol Head Neck Surg 2005; 131: 793-795
  • 132 Bielamowicz S, Stager SV, Badillo A. et al. Unilateral versus bilateral injections of botulinum toxin in patients with adductor spasmodic dysphonia. J Voice 2002; 16: 117-123
  • 133 Langeveld TP, Drost HA, Baatenburg de Jong RJ. Unilateral versus bilateral botulinum toxin injections in adductor spasmodic dysphonia. Ann Otol Rhinol Laryngol 1998; 107: 280-284
  • 134 Koriwchak MJ, Netterville JL, Snowden T. et al. Alternating unilateral botulinum toxin type A (BOTOX) injections for spasmodic dysphonia. Laryngoscope 1996; 106: 1476-1481
  • 135 Maloney AP, Morrison MD. A comparison of the efficacy of unilateral versus bilateral botulinum toxin injections in the treatment of adductor spasmodic dysphonia. J Otolaryngol 1994; 23: 160-164
  • 136 Adams SG, Hunt EJ, Charles DA. et al. Unilateral versus bilateral botulinum toxin injections in spasmodic dysphonia: acoustic and perceptual results. J Otolaryngol 1993; 22: 171-175
  • 137 Blitzer A. Spasmodic dysphonia and botulinum toxin: experience from the largest treatment series. Eur J Neurol 2010; 17 (Suppl. 01) 28-30
  • 138 Dressler D, Adib Saberi F. New formulation of Botox: complete antibody-induced treatment failure in cervical dystonia. J Neurol Neurosurg Psychiatry 2007; 78 (01) 108-109
  • 139 Sedory Holzer SE, Ludlow CL. The Swallowing Side Effects of Botulinum Toxin Type A Injection in Spasmodic Dysphonia. Laryngoscope 1996; 106: 86-92
  • 140 Venkatesan NN, Johns MM, Hapner ER. et al. Abductor paralysis after botox injection for adductor spasmodic dysphonia. Laryngoscope 2010; 120: 1177-1180
  • 141 Smith ME, Ford CN. Resistance to botulinum toxin injections for spasmodic dysphonia. Arch Otolaryngol Head Neck Surg 2000; 126: 533-535
  • 142 Molgó J, Lemeignan M, Thesleff S. Aminoglycosides and 3,4-diaminopyridine on neuromuscular block caused by botulinum type A toxin. Muscle Nerve 1987; 10: 464-470
  • 143 Sulica L, Blitzer A, Brin MF. et al. Botulinum toxin management of adductor spasmodic dysphonia after failed recurrent laryngeal nerve section. Ann Otol Rhinol Laryngol 2003; 112: 499-505
  • 144 Ptok M, Schönweiler R, Nawka T. Deutsche Gesellschaft für Phoniatrie und Pädaudiologie. „Off-Label-Use“ von Botulinumtoxinpärparaten in der Behandlung der spasmodischen Dysphonie. Stellungnahme der Deutschen Gesellschaft für Phoniatrie und Pädaudiologie. HNO 2004; 52: 45-49
  • 145 Kim JW, Park JH, Park KN. et al. Treatment Efficacy of Electromyography versus Fiberscopy-Guided Botulinum Toxin Injection in Adductor Spasmodic Dysphonia Patients: A Prospective Comparative Study. Scientific World Journal 2014; 2014 327928 doi: 10.1155/2014/327928
  • 146 Blitzer A, Lovelace RE, Brin MF. et al. Electromyographic findings in focal laryngeal dystonia (spastic dysphonia). Ann Otol Rhinol Laryngol 1985; 94: 591-594
  • 147 Reichel G. Spasmodische Dysphonie. In: Reichel G. [Ed] Therapieleitfaden Spastik–Dystonien. 5. Aufl.. Bremen: Unimed; 2012: 159-160
  • 148 Stenner A, Reichel G. 23 Jahre Erfahrungen mit der Ultraschall-EMG-gestützten transkutanen Direktinjektion von Botulinumtoxin in die Mm. vocales beim Adduktor-Typ der spasmodischen Dystonie, Abstracts des 5. Deutschen Botulinumtoxin Kongress. 2015. Berlin:
  • 149 Tang CG, Novakovic D, Mor N. et al. Onabotulinum toxin A dosage trends over time for adductor spasmodic dysphonia: A 15-year experience. Laryngoscope 2016; 126: 678-681